drugset / Trial / NCT04030065

Study to Assess the Effect of Intravenous Supplementation of Omega-3 Fatty Acids on Outcome of Recipients in Living Donor Liver Transplantation

NCT04030065

Phase 2 Unknown 124 enrolled Institute of Liver and Biliary Sciences, India
RandomizedParallel-groupOpen-labelSupportive care

Summary

In this study, the investigators aim to analyse the effect of Omega 3 fatty acid supplementation on recipients undergoing living donor liver transplantation. In Group A, the patients receive Omega 3 fatty acid on preoperative day 1, intraoperatively and up to day 5 post operatively; and the effect of omega 3 fatty acid supplementation on early allograft dysfunction, its correlation with occurrence of postoperative complications and liver regeneration measured by CT volumetry on Day 7. Group B, the patients are controls for the study and hence attempt to find out the effect of omega 3 fatty acid supplementation on outcome of recipients of Living donor liver transplantation. the investigators will analyse the data and elucidate the value of omega 3 fatty acid supplementation in reducing the occurrence of early allograft dysfunction , complications and effect on liver regeneration in recipients of Living donor liver transplantation.

Timeline

Start
2018-12-02
Primary completion
2019-11-30
Completion
2019-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovaza Other / unclassified 10 g Intravenous

Indications

No indication recorded.